Form 4: Lucid Diagnostics Inc. Executive Acquires 300,000 Shares of Common Stock

Michael Adam Gordon, General Counsel and Secretary of Lucid Diagnostics Inc., acquired 300,000 shares of common stock on February 20, 2025, and disposed of 700,000 shares.

Summary

• On February 20, 2025, Michael Adam Gordon, the General Counsel and Secretary of Lucid Diagnostics Inc., acquired 300,000 shares of common stock.
• The acquisition was made under the Issuer's 2018 Equity Plan.
• The price of the acquired shares was $0.
• These shares are restricted stock with a single vesting date of May 20, 2028, and are subject to forfeiture if the service period is not completed.
• Following the transaction, Gordon directly owns 700,000 shares of Lucid Diagnostics Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock ownership.

Risks

• The restricted stock is subject to forfeiture if the required service period is not completed, indicating a potential risk of losing the shares if employment terms are not met.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency regarding the holdings of company executives. It's a standard practice for publicly traded companies to report such transactions to the SEC.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly diluting the ownership base, although the number of shares is relatively small compared to the overall outstanding shares.

Key Dates